On Tuesday, Janux Therapeutics Inc (NASDAQ: JANX) opened higher 6.65% from the last session, before settling in for the closing price of $23.91. Price fluctuations for JANX have ranged from $22.48 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -67.90%. Company’s average yearly earnings per share was noted -52.26% at the time writing. With a float of $53.58 million, this company’s outstanding shares have now reached $59.17 million.
Let’s determine the extent of company efficiency that accounts for 81 employees. In terms of profitability, gross margin is 94.58%, operating margin of -1216.61%, and the pretax margin is -832.71%.
Janux Therapeutics Inc (JANX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Janux Therapeutics Inc is 9.45%, while institutional ownership is 110.29%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -52.26% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Check out the current performance indicators for Janux Therapeutics Inc (JANX). In the past quarter, the stock posted a quick ratio of 58.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 161.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -2.48 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Looking closely at Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days average volume was 0.76 million, which is a drop from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 28.42%.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 26.28%, which indicates a significant decrease from 44.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.46 in the past 14 days, which was lower than the 1.61 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.78, while its 200-day Moving Average is $37.00.
